Product
Ozurdex
Aliases
intravitreal dexamethasone implant, Ozurdex® Ophthalmic Intravitreal Implant
Name
OZURDEX
INN Name
dexamethasone
FDA Approved
Yes
4 clinical trials
1 organization
8 indications
1 document
Indication
Diabetic Macular EdemaIndication
Pars Plana VitrectomyIndication
Dexamethasone Intravitreal ImplantIndication
UveitisIndication
posteriorIndication
IntermediateIndication
PanuveitisClinical trial
A Multi-Center, Randomized, Parallel-Group, Phase 2, Masked, Three-Arm Trial to Compare Safety, Tolerability, Efficacy, and Durability of Two Dose Levels of Suprachoroidal Sustained-Release OXU-001 (Dexamethasone Microspheres; DEXAspheres®) Using the Oxulumis® Illuminated Microcatheterization Device Compared With Intravitreal Dexamethasone Implant (OZURDEX®) in Subjects With Diabetic Macular Edema (OXEYE)Status: Active (not recruiting), Estimated PCD: 2024-11-30
Clinical trial
The Use of a Combination of Ozurdex and Eylea Versus Eylea Monotherapy for Diabetic Macular Edema: A Prospective, Comparative TrialStatus: Completed, Estimated PCD: 2022-10-27
Clinical trial
Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Ozurdex as Monotherapy for Treatment of Non-infectious Intermediate, Posterior, or PanuveitisStatus: Recruiting, Estimated PCD: 2027-09-30
Document
DailyMed Label: OZURDEXOrganization
Allergan, Inc.